Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm in exchange for a 26.4% stake in the German group.
The deal is one of the clearest recent examples of a large drugmaker separating its older, off-patent products from its innovative pipeline, while keeping a financial interest in their future.
The deal at a glance
- Medicines: 20 mature medicines, including the anticoagulant Lovenox/Clexane (enoxaparin), excluding US sales
- Sites: Csanyikvölgy, Hungary (about 400 staff); Jurong, Singapore (about 100); Ploërmel, France (about 65)
- Payment: Sanofi receives a 26.4% equity stake in Cheplapharm
- Timeline: Commercial transfer begins in Q1 2027, with the sites following. Completion is expected by Q3 2027
- Guidance: Sanofi says the deal should not affect its 2026 financial guidance
A long relationship
Sanofi and Cheplapharm have worked together since 2014, and Cheplapharm has bought products from Sanofi’s mature portfolio before. Cheplapharm says existing employment arrangements and collective agreements at the three sites will be kept when ownership changes.
Why it matters
- Focus on innovation. Sanofi says the move lets it concentrate on new medicines while its older products keep reaching patients.
- Equity instead of cash. Taking a stake rather than a cash price keeps Sanofi aligned with the portfolio’s performance.
- A wider trend. With a wave of patent expiries ahead, more large drugmakers are reshaping how they manage mature brands, often through structured deals like this one.
What it means for the supply chain
For buyers of these medicines, the main questions are about continuity. A change of marketing authorisation holder and manufacturer can bring new supply agreements, labelling and packaging changes, and updated contacts for orders and quality issues. The phased transfer through 2027 should help, but hospital and pharmacy buyers using Lovenox/Clexane outside the US should watch for transition notices.
For the three plants, the move to a company focused on established medicines could bring new products and investment over time.
The bottom line
Sanofi’s deal with Cheplapharm moves 20 established brands and three plants into specialist hands while keeping Sanofi invested. Expect the practical changes for buyers to arrive from early 2027.
Frequently Asked Questions
What is Sanofi transferring to Cheplapharm? 20 mature medicines and three manufacturing sites in Hungary, Singapore and France.
What does Sanofi get in return? A 26.4% equity stake in Cheplapharm.
Is Lovenox included? Yes, Lovenox/Clexane (enoxaparin) is included, excluding US sales.
When will the transfer happen? Commercial transfer begins in Q1 2027, with completion expected by Q3 2027.
What happens to staff at the sites? Cheplapharm says existing employment arrangements and collective agreements will be kept.
Sources
| Source | Used for |
|---|---|
| Sanofi press release | Deal terms, medicines, sites and timeline |
| Pharmaceutical Technology (PharmTech) | Deal details and industry context |
| Indian Pharma Post | Site staffing figures, timeline and Cheplapharm leadership |
| Bio-IT World | Deal summary |
Additional Resources
| Resource | What you’ll find |
|---|---|
| Sanofi investor relations | Company strategy and financial guidance |
| Cheplapharm | Company profile and product portfolio |
| European Medicines Agency (EMA) | Marketing authorisation transfers in the EU |
| Medicines for Europe | Off-patent and generic medicines industry information |
Data note: The full list of the 20 medicines was not available in reporting, so only Lovenox/Clexane is named.